Breaking News, Collaborations & Alliances

Intravacc Awarded 633K CARB-X Funding

Aims to develop vaccine that prevents gonorrhea infections.

Intravacc, a company involved in translational research and development of preventive and therapeutic vaccines, has been awarded $633,000 from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit organization for the development of a preventive vaccine against Neisseria gonorrhoeae (NG). The vaccine will be developed on Intravacc’s outer membrane vesicle (OMV) platform technology. The CARB-X award supports the development of Intravacc’s meningoco...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters